menu
    • menu
    [{"orgOrder":0,"company":"Mundipharma","sponsor":"Biosolution","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"GERMANY","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"Chondrocytes","moa":"","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"","sponsorNew":"Mundipharma \/ Biosolution Co. Ltd","highestDevelopmentStatusID":"1","companyTruncated":"Mundipharma \/ Biosolution Co. Ltd"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Samsung Bioepis","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"GERMANY","productType":"Large molecule","year":"2020","type":"Partnership","leadProduct":"Adalimumab","moa":"TNF alpha","graph1":"Immunology","graph2":"Approved","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mundipharma \/ Samsung Bioepis","highestDevelopmentStatusID":"12","companyTruncated":"Mundipharma \/ Samsung Bioepis"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Povidone-Iodine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gargle And Mouthwash","sponsorNew":"Mundipharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Mundipharma \/ Not Applicable"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tinostamustine","moa":"HDAC","graph1":"Oncology","graph2":"Phase I","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mundipharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Mundipharma \/ Not Applicable"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Rezafungin","moa":"? (1, 3)-D- glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mundipharma \/ Cidara Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Mundipharma \/ Cidara Therapeutics"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Rezafungin","moa":"? (1, 3)-D- glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mundipharma \/ Mundi Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Mundipharma \/ Mundi Pharma"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Rezafungin","moa":"? (1, 3)-D- glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mundipharma \/ Cidara Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Mundipharma \/ Cidara Therapeutics"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Rezafungin","moa":"? (1, 3)-D- glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mundipharma \/ Mundipharma","highestDevelopmentStatusID":"12","companyTruncated":"Mundipharma \/ Mundipharma"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Rezafungin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mundipharma \/ Cidara Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Mundipharma \/ Cidara Therapeutics"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Rezafungin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Mundipharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mundipharma \/ Not Applicable"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2022","type":"Licensing Agreement","leadProduct":"Rezafungin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mundipharma","amount2":0.56999999999999995,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.56999999999999995,"dosageForm":"Injectable\/Injection","sponsorNew":"Mundipharma \/ Mundipharma","highestDevelopmentStatusID":"10","companyTruncated":"Mundipharma \/ Mundipharma"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Rezafungin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Mundipharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Mundipharma \/ Not Applicable"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Rezafungin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mundipharma \/ Cidara Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Mundipharma \/ Cidara Therapeutics"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2024","type":"Partnership","leadProduct":"Rezafungin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Mundipharma","amount2":0.56999999999999995,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.56999999999999995,"dosageForm":"Infusion","sponsorNew":"Mundipharma \/ Mundipharma","highestDevelopmentStatusID":"12","companyTruncated":"Mundipharma \/ Mundipharma"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Rezafungin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mundipharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mundipharma \/ Not Applicable"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Vectura Ltd","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Fluticasone Propionate","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Mundipharma \/ Vectura Ltd","highestDevelopmentStatusID":"12","companyTruncated":"Mundipharma \/ Vectura Ltd"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Cidara Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Divestment","leadProduct":"Rezafungin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mundipharma \/ Mundipharma","highestDevelopmentStatusID":"12","companyTruncated":"Mundipharma \/ Mundipharma"},{"orgOrder":0,"company":"Mundipharma","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Canagliflozin","moa":"SGLT2","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mundipharma \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"Mundipharma \/ GSK"}]

    Find Clinical Drug Pipeline Developments & Deals by Mundipharma

    Menu

    Mundipharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Mundipharma

                            Germany arrow
                            The Generic Rx Session
                            Not Confirmed

                            Mundipharma

                            Germany arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rezafungin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Recipient : Cidara Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Cidara Therapeutics Divests Rezafungin to Focus on Advancing Cloudbreak DFC Pipeline

                            Details : Through the divestment, Mundipharma received the rights for Rezzayo (rezafungin acetate), an echinocandin antifungal, approved for the treatment of invasive candidiasis in adults.

                            Product Name : Rezzayo

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 24, 2024

                            Lead Product(s) : Rezafungin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Recipient : Cidara Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Mundipharma

                            Germany arrow
                            The Generic Rx Session
                            Not Confirmed

                            Mundipharma

                            Germany arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fluticasone Propionate,Formoterol Fumarate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Approved

                            Sponsor : Vectura Ltd

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Mundipharma, Vectura Plan to Reformulate flutiform® to Reduce Carbon Footprint

                            Details : Two companies have a collaboration agreement to develop an environmentally friendly propellant for flutiform® (fluticasone propionate/formoterol fumarate) in a pMDI formulation.

                            Product Name : Flutiform

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 16, 2024

                            Lead Product(s) : Fluticasone Propionate,Formoterol Fumarate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Approved

                            Sponsor : Vectura Ltd

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Mundipharma

                            Germany arrow
                            The Generic Rx Session
                            Not Confirmed

                            Mundipharma

                            Germany arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rezafungin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Recipient : Cidara Therapeutics

                            Deal Size : $568.0 million

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Cidara Receives $11.14M Milestone Payment After European Approval of REZZAYO

                            Details : The payment triggered under the agreement is following the European approval of Rezzayo (rezafungin acetate), a novel, once-weekly echinocandin antifungal approved for invasive candidiasis in adults.

                            Product Name : Rezzayo

                            Product Type : Peptide

                            Upfront Cash : $39.0 million

                            February 12, 2024

                            Lead Product(s) : Rezafungin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Recipient : Cidara Therapeutics

                            Deal Size : $568.0 million

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Mundipharma

                            Germany arrow
                            The Generic Rx Session
                            Not Confirmed

                            Mundipharma

                            Germany arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rezafungin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Mundipharma Announces European Approval of REZZAYO® (rezafungin) for the Treatment of Invasive Candidiasis in...

                            Details : Rezzayo (rezafungin) is an echinocandin antifungal indicated in patients 18 years of age or older who have limited or no alternative options for the treatment of candidemia and invasive candidiasis.

                            Product Name : Rezzayo

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 22, 2023

                            Lead Product(s) : Rezafungin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Mundipharma

                            Germany arrow
                            The Generic Rx Session
                            Not Confirmed

                            Mundipharma

                            Germany arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rezafungin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Cidara Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Mundipharma and Cidara Therapeutics Receive Positive CHMP Opinion for Rezafungin for the Treatment of Invasive...

                            Details : Rezafungin is a novel once-weekly echinocandin being developed for both the treatment and prevention of serious fungal infections, such as invasive candidiasis and candidemia.

                            Product Name : Rezzayo

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 13, 2023

                            Lead Product(s) : Rezafungin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Cidara Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Mundipharma

                            Germany arrow
                            The Generic Rx Session
                            Not Confirmed

                            Mundipharma

                            Germany arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rezafungin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Napp Announces Acceptance of their Rezafungin Marketing Authorisation Application for the Treatment of Invasiv...

                            Details : CD101 (rezafungin) is a novel, once-weekly echinocandin being developed for both the treatment and prevention of serious fungal infections,demonstrated non-inferiority to the current standard of care in the treatment of candidemia and/or invasive candidi...

                            Product Name : CD101

                            Product Type : Peptide

                            Upfront Cash : Not Applicable

                            November 16, 2022

                            Lead Product(s) : Rezafungin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Mundipharma

                            Germany arrow
                            The Generic Rx Session
                            Not Confirmed

                            Mundipharma

                            Germany arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rezafungin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Recipient : Cidara Therapeutics

                            Deal Size : $568.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Cidara Therapeutics Receives $11.1 Million Milestone Payment from Mundipharma

                            Details : Rezafungin is a novel once-weekly echinocandin being developed for both the treatment and prevention of serious fungal infections, such as candidemia and invasive candidiasis.

                            Product Name : CD101

                            Product Type : Peptide

                            Upfront Cash : $30.0 million

                            October 04, 2022

                            Lead Product(s) : Rezafungin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Recipient : Cidara Therapeutics

                            Deal Size : $568.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Mundipharma

                            Germany arrow
                            The Generic Rx Session
                            Not Confirmed

                            Mundipharma

                            Germany arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rezafungin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            European Medicines Agency Accepts Rezafungin Marketing Authorisation Application for the Treatment of Invasive...

                            Details : European Medicines Agency filing is supported by the pivotal ReSTORE Phase III clinical trial results, where rezafungin (echinocandin/CD101) demonstrated non-inferiority to the current standard of care, caspofungin in the treatment of candidemia and/or i...

                            Product Name : CD101

                            Product Type : Peptide

                            Upfront Cash : Not Applicable

                            August 22, 2022

                            Lead Product(s) : Rezafungin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Mundipharma

                            Germany arrow
                            The Generic Rx Session
                            Not Confirmed

                            Mundipharma

                            Germany arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rezafungin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Cidara Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Mundipharma and Cidara Therapeutics Announce First Presentation of Results from Global Phase 3 ReSTORE Trial o...

                            Details : Results from ReSTORE showed primary endpoints were met with, 23.7% all-cause mortality on day 30 for rezafungin compared to 21.3% for caspofungin global cure on day 14 of 59.1% for rezafungin and 60.6% for caspofungin.

                            Product Name : CD101

                            Product Type : Peptide

                            Upfront Cash : Not Applicable

                            April 25, 2022

                            Lead Product(s) : Rezafungin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Cidara Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Mundipharma

                            Germany arrow
                            The Generic Rx Session
                            Not Confirmed

                            Mundipharma

                            Germany arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rezafungin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Recipient : Cidara Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Cidara Therapeutics and Mundipharma to Present Results from Global Phase 3 ReSTORE Trial of Rezafungin for the...

                            Details : Result, did not demonstrate highly potent antifungal properties of CD101 against Candida in preclinical animal models of VVC, CD101 IV has enhanced potency and is only once-weekly therapy intended for treatment and prevention of life-threatening invasive...

                            Product Name : CD101

                            Product Type : Peptide

                            Upfront Cash : Not Applicable

                            April 14, 2022

                            Lead Product(s) : Rezafungin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Recipient : Cidara Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth